- Home
- GNS vs CVM Comparison
GNS vs CVM Comparison
Compare GNS & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNS | CVM |
|---|---|---|
| Founded | 2002 | 1983 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 30.1M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GNS | CVM |
|---|---|---|
| Price | $0.15 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 108.3K |
| Earning Date | 03-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | $156.26 | N/A |
| Revenue Next Year | $35.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.15 | $0.89 |
| 52 Week High | $1.06 | $10.83 |
Technical Indicators
Market Signals| Indicator | GNS | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 54.53 |
| Support Level | $0.15 | $0.95 |
| Resistance Level | $0.23 | $1.59 |
| Average True Range (ATR) | 0.01 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 9.36 | 36.07 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.